Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAST Cells Plus Docetaxel in Advanced NSCLC Resistant to PD-1 Inhibitors
NCT07330050Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Whole Agonist-Stimulated T cells in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate at 24 months. Started Dec 2025; status: recruiting.
02
Drugs
Whole Agonist-Stimulated T cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07330050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07330050.